Amneal Pharmaceuticals, Inc. (AMRX)

NMS – Real Time Price. Currency in USD

17.23

-0.09 (-0.52%)

At close: Jun 26, 2026, 4:00 PM EDT

16.85

-0.38 (-2.21%)

After-hours: Jun 26, 2026, 7:17 PM EDT

11.06.2026

AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?

Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

10.06.2026

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

Amneal's Commitment Helps Support a Reliable Supply of Essential Medicines for Uninsured and Underserved Patients Nationwide NASHVILLE, Tenn., June 10, 2026 /PRNewswire/ -- Dispensary of Hope announced the launch of its national "Hope Alliance" campaign this year, a strategic initiative designed to expand access to high-quality, longer-dated medications for low-income and uninsured patients across the United States.

09.06.2026

Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase

Amneal Pharmaceuticals NASDAQ: AMRX Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics portfolio, a newly expanded biosimilars platform and specialty product launches.

09.06.2026

Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

09.06.2026

Amneal and Pfizer GLP-1 Deal: New Growth Lever?

AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.

09.06.2026

Is Amneal a Buy Before Rytary Generic Erosion?

AMRX faces Rytary generic pressure in 2026, but growth in generics, injectables, biosimilars, and higher profitability targets could support its outlook.

09.06.2026

What's Driving Amneal's 2026 Growth Outlook?

AMRX's 2026 outlook is driven by higher profit expectations, a steady launch cadence, and growth from complex generics, injectables, and specialty brands.

Videos

No Data

There is no data to display

Press releases

10.06.2026

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

05.06.2026

Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease

BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, which are being presented at the Advanced Therapeutics in Movement & Related Disorders® (ATRMD) 2026 Congress on June 5, 2026.

04.06.2026

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution

Ready-to-use romidepsin formulation; offers a more convenient alternative to lyophilized powder requiring reconstitution Competitive Generic Therapy approval provides 180 days of market exclusivity and further expands Amneal's differentiated injectables portfolio BRIDGEWATER, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's romidepsin injection solution, 27.5 mg/5.5 mL, supplied in single-dose, ready-to-use vials.

07.05.2026

Amneal Reports First Quarter 2026 Financial Results

‒ Q1 2026 Net Revenue of $723 million ; GAAP Net Income of $62 million ; Diluted Income per Share of $0.19 ‒ ‒ Adjusted EBITDA of $202 million ; Adjusted Diluted EPS of $0.27 ‒ ‒ No Change from Preliminary Results Previously Announced on April 22, 2026 ‒ ‒ Affirms Previously Announced Increase in 2026 Full Year Guidance ‒

Amneal Pharmaceuticals, Inc. (AMRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Amneal Pharmaceuticals, Inc. (AMRX)

AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase

Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Amneal and Pfizer GLP-1 Deal: New Growth Lever?

Is Amneal a Buy Before Rytary Generic Erosion?

What's Driving Amneal's 2026 Growth Outlook?

Videos

No Data

Press releases

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution

Amneal Reports First Quarter 2026 Financial Results

AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase

Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Amneal and Pfizer GLP-1 Deal: New Growth Lever?

Is Amneal a Buy Before Rytary Generic Erosion?

What's Driving Amneal's 2026 Growth Outlook?

Videos

No Data

Press releases

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution

Amneal Reports First Quarter 2026 Financial Results

Search stocks

Amneal Pharmaceuticals, Inc. (AMRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Amneal Pharmaceuticals, Inc. (AMRX)

AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase

Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Amneal and Pfizer GLP-1 Deal: New Growth Lever?

Is Amneal a Buy Before Rytary Generic Erosion?

What's Driving Amneal's 2026 Growth Outlook?

Videos

No Data

Press releases

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution

Amneal Reports First Quarter 2026 Financial Results

AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase

Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Amneal and Pfizer GLP-1 Deal: New Growth Lever?

Is Amneal a Buy Before Rytary Generic Erosion?

What's Driving Amneal's 2026 Growth Outlook?

Videos

No Data

Press releases

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution

Amneal Reports First Quarter 2026 Financial Results